Galectin-3 predicts the risk of ventricular tachycardia in ischemic heart failure patients with implantable cardioverter-defibrillator

Back

HFA Premium Access

Galectin-3 predicts the risk of ventricular tachycardia in ischemic heart failure patients with implantable cardioverter-defibrillator

Session: Chronic Heart Failure - Pathophysiology and Mechanisms 2

Topic: Systolic Ventricular Dysfunction

Speaker: Doctor E. Grakova (Tomsk, RU)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Doctor Elena Grakova

Cardiology Research Institute, Tomsk National Research Medical Centre of Russian Academy of Science, Tomsk (Russian Federation)

0 follower

9 more presentations in this session

Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial

Speaker: Doctor C. Lam (Singapore, SG)

Long-term outcomes in heart failure with preserved ejection fraction: predictors of cardiovascular and non-cardiovascular mortality

Speaker: Ms A. Shahim (Stockholm, SE)

The impact of multimorbidity on mortality in heart failure with reduced ejection fraction (HFrEF): Which comorbidities matter most?

Speaker: Doctor P. Dewan (Glasgow, GB)

Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)

Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial

Speaker: Doctor R. Mentz (Durham, US)

Access the full session

Chronic Heart Failure - Pathophysiology and Mechanisms 2

Speakers: Doctor E. Grakova, Doctor C. Lam, Ms A. Shahim, Doctor P. Dewan, Doctor K. Docherty...

Access

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources